new psoriasis preclinical evaluation platform - newsletter - january 2014
TRANSCRIPT
NEW! PSORIASIS PRECLINICAL EVALUATION PLATFORM Biomedcode has recently developed an Imiquimod-based Psoriasis preclinical evaluation platform. INDICATIONS • Rapid and convenient model for the evaluation of new therapies targeting psoriasis • Fast screening of biologics and small molecules • Evaluation of topical application formulations • Evaluation of humanized therapeutics
IMIQUIMOD-INDUCED PSORIASIS Topical application of Aldara (5% Imiquimod) results in the fast development of psoriasis-like lesions. The pathology is similar to human disease characterized by skin erythema, scaling and thickness and at the histopathological level hyperproliferation of keratinocytes and inflammatory infiltrates. DISEASE CAN BE INDUCED IN • wild type animals • human transgenic animals READ-OUTS •In vivo scoring •Spleen Weight •Histopathology
0
1
2
3
4
5
6
1
Ηis
top
ath
olo
gica
l sco
re
0,000
0,002
0,004
0,006
0,008
0,010
0,012
1
Sple
en w
eigh
t/B
od
y w
eigh
t
About Us Biomedcode is a highly innovative CRO that provides preclinical drug evaluation services offering scientific consultation and custom-tailored solutions for the optimized evaluation of novel and biosimilar pharmaceuticals. Biomedcode offers a diverse array of state-of-the-art preclinical evaluation platforms based on a unique collection of mouse models that closely mimic human inflammatory diseases. Biomedcode’s human TNF transgenic models were instrumental in providing the preclinical rationale for the development of anti-TNF therapies in arthritis.
Normal skin Psoriatic skin
0,000
0,002
0,004
0,006
0,008
0,010
0,012
1
Sple
en w
eigh
t/B
od
y w
eigh
t
Aldara
Aldara+Clobetasol
Naïve
Newsletter Issue: January 2014
www.biomedcode.com
HUMANIZED MODELS
hTNF hTNFR2hTNFR1KI IL17a
SPONTANEOUSArthritis (hTNF/hTNFR1)
• Tg197• hTNFR1Tg197• Tg3647• Tg5453• TNF DARE
IntestinalInflammation (TNF)
TNF DARE
INDUCEDArthritisCAIA
Intestinal InflammationTNBS colitis
Multiple SclerosisEAE
Psoriasis (NEW!)IMQ model
LPS, LPS/D-gal
DISEASE MODELS
0,2
0,4
0,6
0,8
1,0
1,2
1,4
D2 D3 D4 D5
Skin
th
ickn
ess